VisionHealth GmbH

https://www.visionhealth.gmbh

VisionHealth GmbH is a pioneer of digital therapy support for respiratory diseases. In cooperation with research institutions and selected industry partners, medical experts and IT experts, VisionHealth develops innovative and unique digital health solutions enabling sustainable improvements to existing standard therapies for patients with chronic lung diseases like asthma and COPD. The Munich-based private company was founded in 2017 by inhalation therapy specialists. Investors include business angels and private investors with many years of industry expertise, particularly in inhalation therapies. www.visionhealth.gmbh About Kata® Kata® is a VisionHealth proprietary platform based on artificial intelligence to support inhalation therapy. The aim of the Kata® app for patients is to optimize the drug inhalation therapy of chronic lung diseases through digital support by help of augmented reality using the smartphone camera for immediate feedback and correction. Clinical evidence shows that patients frequently fail to correctly perform their necessary and regular inhalation due to a lack of therapy adherence or knowledge. As a result, the prescribed medications are not adequately delivered to the respiratory airways. A multitude of different devices for drug inhalation increases the training effort for physicians and patients and makes therapy monitoring almost impossible. This issue affects around 250 million people worldwide suffering from chronic lung diseases to whom Kata® could bring urgently needed relief. Kata® is a proprietary platform application providing a completely novel and unique combination of artificial intelligence (AI) and computer animation. Kata® is among the first digital applications to have received medical device certification. Protection of patient sensitive data is ensured via certified ISMS and VisionHealth’s improved quality management system. A modified Kata® app for clinical trials (Kata® Clinical) combines data and patient management to enhance the participants‘ experience and improve study outcomes at the same time. Based on the customized adaptation to the specific needs of a study, data collection and management can be conducted more efficiently and are less error-prone due to automation. Kata® Clinical was launched in 2021 and has convinced in a clinical trial with sterna biologicals GmbH, Marburg, Germany. Kata® Clinical is also part of the offering portfolio of several CROs, including Alcedis, Kottmann, and Labcorp. *

	Start	2017-07-01 established
	Industry	digital therapeutic (dTx)
	Industry 2	Kata® App

	Region	München (Munich)
	Country	Germany
	Street	72 Landsberger Str.
	City	80339 München
		Address record changed: 2023-03-17

Basic data	Employees	n. a.

		* Document for »About Section«: VisionHealth GmbH. (2/27/23). "Press Release: VisionHealth Raises 3 Million Euro to Finance Extended COPD and Asthma Study for Market Preparation of Kata, an Innovative Digital Therapeutic for Improved Inhalation". Munich.

		Record changed: 2024-12-29

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for VisionHealth GmbH

[1] VisionHealth GmbH. (2/27/23). "Press Release: VisionHealth Raises 3 Million Euro to Finance Extended COPD and Asthma Study for Market Preparation of Kata, an Innovative Digital Therapeutic for Improved Inhalation". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)